Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I see. You think it is still a big opportunity for ENTA, don't you? I understand it. Compared to its Market Cap. it is huge, isn't it?
What I meant about transition is PFE says one of the reasons for poor revenue on Paxlovid is they are changing their method of sales to commercial markets rather than to government deals. That's what I understood from their recent conference call. I was asking you guys' opinion on it. Whether it would be better for PFE's Paxlovid sales or not.
Thank you for your elaboration. I mean it.
I've seen the data of EDP-235 and it has more steep data than Paxlovid. But I am not a doctor, and I don't exactly know how much it has more powerful efficacy than Paxlovid. I hope it is way better for lots of patients and us. That was the reason I posted it. Whoever saw the graph would know that simple information. Don't be mad. I apologize for my poor knowledge. I am just an investor who is trying to grasp about this company for my future investment.
Anyway, I've listened about the 'waste water' in 3Q C.C. of Enanta. Do you happen to know where to see the data of it?
and when did I say something wrong about Paxlovid sales? I've only asked about 23.2Q. revenue. Isn't it 143m? I've seen it on 10Q, sec.gov.
I see, thank you. But the guidance is still less than last year, like 1 of 3. Do you think the transition to traditional commercial markets is better for Paxlovid's revenue? Care to elaborate?
I have heard of the seasonality of them and I have seen cases of covid-19 spike. But when you go to CDC and see the data of patients, which is not that many. Look at 2022 2Q revenue. Don't you think it is almost the end of covid?
What are you talking about? Are you sure it is 1.49b? Is U.S. revenue like 1.39m?
PFE says 2Q23 is a nadir, as explained in #msg-172488867.
More like 1.49 Billion in Q2.
Have you seen the 2Q revenue of Paxlovid, Pfizer? It is 143m. Do you think covid is over or it is just because of the cycle?
AVIR modifies phase-3 protocol for COVID antiviral, bemnifosbuvir:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172556375
Yes, I will post ENTA's pro forma net cash after I have studied the 2Q23 10-Q, which was filed this afternoon.
"Cash" means actual bank-account cash or cash-equivalent securities such as money-market funds and Treasury bills. ENTA is not in the investment business.
I understand that ENTA's cash may carry them for a little while, but what do they do with their stash; Is it invested in US Treasuries? Can the company do anything with the money that the board approves, what options does a company like ENTA have for investing cash?
Listen again. They said they have to talk to regulators first. You don’t have the facts straight
Which company do you think would be the partner for SPRINT? Was there any discussion on it? I mean, I could not find it yet.
And what is the most important factor to substitute Paxlovid when it is approved? I guess it would be the absence of ritonavir. Do you agree with this? By the looks of the data, it doesn't show strong potency compared to Paxlovid.
They repeated many times that their regulatory path is through a partnership (they’ve done it with ABBV before for HCV). ENTA definitely doesn’t have a bandwidth to run multi-thousand-patient global Phase III studies
That job ad you caught a few weeks ago makes more sense in light of the disclosure on today’s CC that ENTA has initiated discovery work in an undisclosed non-virology area.
On today’s call, there was an admission that there was no regulatory path for the Covid drug. This is pretty disappointing.
Massive cash burn on HMPV. What’s the point?
Combination treatment for RSV remains a possibility, as discussed on today's CC.
I suppose that, theoretically, fusion inhibitors should be better for prophylaxis and N-inhibitors for treatment. However, other properties such as potency, safety, and PK might be more important. It's likely that, as with HIV and HCV, a combination of compounds with different modes of action would have significant synergy."
ENTA FY3Q23* financials—6/30/23_cash=$393M:
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-36
FY3Q23 royalty revenue was $18.9M.†
FY3Q23 R&D expenses were $43.0M, consistent with the quarterly run rate of ENTA’s updated FY2023 guidance of $165-175M.
FY3Q23 SG&A expenses were $12.6M, consistent with the quarterly run rate of ENTA’s updated FY2023 guidance of $50-55M.
†ENTA’s partial sale of Mavyret royalties took effect on 7/1/23, so it did not affect the FY3Q23 income statement.
*ENTA’s fiscal years end on September 30.
Fusion inhibitors are not effective once the virus has entered a particular cell. N inhibitors, on the other hand, impede viral replication inside an infected cell.
Is there anyone who knows if N inhibitor is better than Fusion inhibitor in RSV?
The NIH is running trials to assess therapies that might help combat long Covid. I guess Jake should tell the NIH they don't know what they are doing.
Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023:
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-host-conference-call-august-7-430-pm-et-1
In 2020 the lowest it went was in the $40s. The only time outside of 2013 and 2023 that ENTA ever neared the $18s was in 2016, and the close that day was $21.72 on 7/28/16.
These low prices today may also reflect broader economic fears, but the lack of faith in Enanta is real.
While I expect Enanta to pursue high risk / high reward opportunities and I believe that their molecule development teams are very skilled I am sometimes troubled by their follow the others forays such as RNA destabilizers and now possibly immunotherapies.
Wow, this is a full round tripper from $18 a few years ago..
Paxlovid sales for the first quarter came in at $4.1 billion, which far exceeded Wall Street's expectation of $2.7 billion. The result also was a $2.8 billion increase from the same period in 2022. Pfizer chalked up the performance to strong demand in China and to new launches in other international markets.
Pfizer’s infringement has damaged and will continue to damage Enanta, which is
entitled to recover damages adequate to compensate for Pfizer’s infringement in an amount to be
determined at trial, and in any event no less than a reasonable royalty for the use made by Pfizer
of Enanta’s invention.
PRAYERS FOR RELIEF
WHEREFORE, Enanta Pharmaceuticals, Inc. respectfully requests that this Court:
a. Enter judgment that Pfizer has infringed the ’953 Patent;
b. Award damages adequate to compensate Enanta for Pfizer’s infringement
together with pre-judgment and post-judgment interest and costs under 35 U.S.C.
§ 284;
c. Award treble damages for Pfizer’s willful infringement;
d. Enter judgment that this case is exceptional and award Enanta its reasonable
attorneys’ fees, costs, and expenses, under 35 U.S.C. § 285; and
e. Award such other and further relief as this Court may deem just and proper.
ENTA reaches new ten year low at 18.79/share. Buy the dip? It looks like this might be going below the IPO price, probably to below $15/share in the near future.
Is there a deal coming? So what’s the Enterprise Value (EV) now?
Caveat Emptor
With the stock at 10 year low's around $20/share, anyone have any thoughts/comments on a buy out potential?
Could be related to the HBV program. A few companies are testing combination regimens in HBV that include an immunotherapy component.
...as Enanta broadens its modalities of focus into the immunology therapeutic area.
I felt it was important that I support my use of the word "immunotherapy" so I am providing the above statement as declared on the job description. Growth or a jump, you choose.
Enanta adding a new direction, immunotherapy (seemingly). Enanta has posted a position for a peptide chemist. I do have some experience in both monoclonal antibody development and immunotherapy, but I do not have comments other than to mention that this is the first insight I have become aware of in regard to Enanta's endeavors in such direction.
Will wonders never cease! ENTA is up for the 3rd day in a row and closed over $22. Still a long, long way to go but it feels nice to see some positive sentiment.
Happy Independence Day!
With ENTA stock continuing to take a beating, I thought I would explain why I remain bullish and a buyer.
The EDP-235 data was quite good. It showed a good safety profile, showed a statistically significant improvement in symptoms and reducing their duration, in a highly vaccinated low risk population that had mostly been previously infected. In stark contrast, Paxlovid failed to do that in an similar low risk population, but one in which most were not yet vaccinated or infected. Despite this effectiveness in improving symptoms, the knock that drove ENTA down was the lack of viral reduction in nasal swabs, even though nasal swabs isn't a metric for approval and Remdesivir didn't do that either yet got FDA approval.
That left the conundrum of why EDP-235 showed robust anti-viral effects with regards to symptoms but not in nasal viral swabs. The anomaly was a rapid decreases nasal swab viral levels in the control group, possibly due to previous infection with Covid generating strong IgM responses. That would explain the rapid clearance in mucosal membranes in controls. ENTA looked closely and saw that if they examined patients who hadn't been previously infected, those without anti-nucleocapsid antibodies, there was indeed a robust viral reduction with EDP-235. Given that the vast majority in the EDP-235 phase 2 trial had been previously infected, that would explain why no difference was seen. The general population doesn't care but prospective partners will be assured. I know I am.
If no funding or co-marketing by $ENTA: $75M+ up-front cash; $250M+ regulatory milestones; $150M+ sales milestones; ~20% royalty on worldwide sales.
I too am hoping for more, although 2B in milestones/yr near term sounds pretty good, still the upfront is lower than I am hoping. I do not have the knowledge base to assess the current market value for this type of asset given the potential sales and potential losses if the drug does not make it to market. I am hoping for a buyout as I feel that ENANTA has demonstrated the creation of small molecule virus inhibitor development machine. Long ago I, and others too (from memory) were hoping for an 8B buyout price, that would be fine by me.
Let me know if my expectations are too high.
I just love it when the market lets me buy stocks I like at a discount. I have already increased my shares of ENTA by 25% since its drop after the successful EDP-235 phase 2 trial. I will buy more
ENTA, new 10 year low today. Deal signed?
ENTA’s PR on phase-1 data for EDP-323, an RSV L-protein inhibitor:
https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-positive-data-phase-1-0
Enanta posts positive phase one data on EDP-323 initiating Human Challenge Study early Q4 with FDA fast track designation.
Followers
|
98
|
Posters
|
|
Posts (Today)
|
4
|
Posts (Total)
|
3316
|
Created
|
03/20/13
|
Type
|
Free
|
Moderators DewDiligence |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |